Pharming Group Q3 Revenue Rises 21%, Operating Profit Up 89%
Pharming reported preliminary unaudited Q3 revenue of $117.6 million, up 21% year over year, and operating profit of $29.9 million, up 89%. RUCONEST revenue rose 14% to $93.8 million; Joenja revenue grew 58% to $23.8 million.
Story updates
06:11:27 AM UTC
SquawkNews
Pharming Group Q3 revenue rises on US demand; tightens guidance
06:12:13 AM UTC
SquawkNews
Pharming Group Q3 revenue rises on US demand; tightens guidance Overview Netherlands biotech firm's
Pharming Group N.V. reported preliminary unaudited Q3 revenue of $117.6M, up 21% YoY, with operating profit up 89% to $29.9M. RUCONEST rose 14% to $93.8M and Joenja grew 58% to $23.8M.Material DetailsContext by AI AnalystResults show mid-cycle execution with RUCONEST stabilization and Joenja expans…